Foamix Submits New Drug Application to U.S. FDA for FMX103 for the Treatment of Moderate-to-Severe Papulopustular Rosacea

REHOVOT, Israel and BRIDGEWATER, N.J., Aug. 5, 2019 -- (Healthcare Sales & Marketing Network) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical th... Biopharmaceuticals, Dermatology, FDA Foamix Pharmaceuticals, rosacea
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news